JSM 2012 Home

JSM 2012 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Online Program Home

Abstract Details

Activity Number: 231
Type: Topic Contributed
Date/Time: Monday, July 30, 2012 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract - #306171
Title: Adapting from Phase III to Phase II at an Interim Analysis
Author(s): Keaven Anderson*+ and Xiaoyun (Nicole) Li
Companies: Merck and Merck & Co.
Address: 351 N. Sumneytown Pike, North Wales, PA, 19454, United States
Keywords: adaptive design ; clinical trials ; group sequential design

For time-to-event trials in oncology, it is often the case that the evidence that a new treatment works is based on a surrogate endpoint from a small trial. Thus, the evidence that the treatment works for a more clinically important endpoint for a definitive trial is limited. Sometimes a Phase III trial with an interim futility analysis is used to limit investment in such cases. The question becomes, if the trial stops for futility, might there still be interest in further developing the new treatment studied? Here we provide a third option to continuing or stopping a Phase III trial. We develop methods to convert a Phase III trial to a Phase II trial that provides full control of different Type I and Type II errors for Phase II and Phase III while also making the conversion rules non-binding. This strategy provides an efficient option for a new treatment in late-stage development accord

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2012 program

2012 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.